文献速递肝病

熊去氧胆酸治疗的 Primary Biliary Cholangitis 患者的主要肝脏并发症:危险因素及发病率与结局的时间趋势

Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome.
PubMed 文献 · Am J Gastroenterol · 2017-12-12

该研究纳入欧洲和北美16个肝脏中心的3224例接受熊去氧胆酸(UDCA)治疗的原发性胆汁性胆管炎(PBC)患者,中位随访8.1年。278例发生腹水、静脉曲张出血和/或肝性脑病,10年累积发生率为9.1%,2000年后降至5.8%;生化应答不佳且APRI>0.54者10年并发症率为37.4%,而应答良好且APRI≤0.54者为3.2%。

要点

  • UDCA治疗的PBC患者中,278/3224例发生腹水、静脉曲张出血和/或肝性脑病,发生率9.7例/1000患者年。
  • 10年累积并发症发生率为9.1%,2000年后诊断者降至5.8%。
  • 生化应答不佳且APRI>0.54者10年并发症率37.4%,应答良好且APRI≤0.54者为3.2%。

核心结论

  • 在这个大型国际队列中,高达15%的UDCA治疗的PBC患者在15年内发生主要非肿瘤性、肝硬化相关肝脏并发症,但累积发病率随时间下降。
  • 对UDCA的生化应答不佳和APRI是这些并发症的独立危险因素。
  • 并发症后的长期结局通常较差,但在过去几十年中有所改善。

研究设计与样本

  • 研究纳入来自16个欧洲和北美肝脏中心的UDCA治疗的PBC患者队列,共3224例。
  • 采用Cox比例风险假设和Kaplan-Meier估计进行分析。

主要发现

  • 中位随访8.1年期间,3224例患者中278例发生腹水、静脉曲张出血和/或肝性脑病,发生率为9.7例/1000患者年。
  • 10年随访时总体累积发生率为9.1%,但2000年后降至5.8%。
  • 诊断日历年较早(P<0.001)、高天冬氨酸氨基转移酶与血小板比值指数(APRI;P<0.001)和生化应答不佳(P<0.001)与未来并发症独立相关。
  • UDCA治疗12个月后生化应答不佳且APRI>0.54的患者10年并发症率为37.4%,而生化应答良好且APRI≤0.54者为3.2%。

关键数值与推荐

  • UDCA治疗12个月后生化应答不佳且APRI>0.54:10年并发症率37.4%。
  • UDCA治疗12个月后生化应答良好且APRI≤0.54:10年并发症率3.2%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: In this era of near universal ursodeoxycholic acid (UDCA) treatment for primary biliary cholangitis (PBC), progression to cirrhosis still occurs in an important proportion of patients. The aim of this study was to describe the incidence of cirrhosis-associated complications in patients with PBC and assess risk factors and impact on survival. METHODS: Cohorts of UDCA-treated patients from 16 European and North-American liver centers were included. We used Cox proportional hazards assumptions and Kaplan-Meier estimates. RESULTS: During 8.1 years' median follow-up, 278 of 3,224 patients developed ascites, variceal bleeding, and/or encephalopathy (incidence rate of 9.7 cases/1,000 patient years). The overall cumulative incidence was 9.1% after 10 years of follow-up, but decreased over time to 5.8% after the year 2000. Earlier calendar year of diagnosis (P<0.001), high aspartate aminotransferase to platelets ratio index (APRI; P<0.001) and biochemical non-response (P<0.001) were independently associated with future complications. Patients with both biochemical non-response and an APRI >0.54 after 12 months of UDCA had a 10-year complication rate of 37.4%, as compared to 3.2% in biochemical responders with an APRI ≤0.54. The 10-year transplantation-free survival after a complication was 9% (time-dependent hazard ratio 21.5; 20.1-22.8). Prognosis after variceal bleeding has improved over time. CONCLUSIONS: In this large international cohort, up to 15% of UDCA-treated PBC patients developed major non-neoplastic, cirrhosis-associated hepatic complications within 15 years, but cumulative incidence has decreased over time. Biochemical non-response to UDCA and APRI were independent risk factors for these complications. Subsequent long-term outcome after complications is generally poor, but has improved over the past decades.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Harms MH, Lammers WJ, Thorburn D, et al. Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. Am J Gastroenterol. 2017. PMID: 29231188. doi:10.1038/ajg.2017.440

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。